The International LAM Registry: a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platform.

BACKGROUND A relative inability to capture a sufficiently large patient population in any one geographic location has traditionally limited research into rare diseases. METHODS AND RESULTS Clinicians interested in the rare disease lymphangioleiomyomatosis (LAM) have worked with the LAM Treatment Alliance, the MIT Media Lab, and Clozure Associates to cooperate in the design of a state-of-the-art data coordination platform that can be used for clinical trials and other research focused on the global LAM patient population. This platform is a component of a set of web-based resources, including a patient self-report data portal, aimed at accelerating research in rare diseases in a rigorous fashion. CONCLUSIONS Collaboration between clinicians, researchers, advocacy groups, and patients can create essential community resource infrastructure to accelerate rare disease research. The International LAM Registry is an example of such an effort. 82.

[1]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[2]  J. Testa,et al.  Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. , 2003, American journal of respiratory and critical care medicine.

[3]  K. Kubo,et al.  The epidemiology of lymphangioleiomyomatosis in Japan: A nationwide cross‐sectional study of presenting features and prognostic factors , 2007, Respirology.

[4]  G. Amann,et al.  Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. , 2003, Human pathology.

[5]  J. Lacronique,et al.  Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). , 1999, Medicine.

[6]  J. Moss,et al.  Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. , 2001, American journal of respiratory and critical care medicine.

[7]  G. Beck,et al.  The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. , 2006, American journal of respiratory and critical care medicine.

[8]  Won Kim,et al.  Introduction to Object-Oriented Databases , 1991, Computer systems.

[9]  J. Kretz Cancer Control , 1942, Nature.

[10]  P. Crino,et al.  The tuberous sclerosis complex. , 2006, The New England journal of medicine.

[11]  G. Downey,et al.  Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. , 2007, American journal of respiratory cell and molecular biology.

[12]  T. Hartman,et al.  High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. , 2000, Mayo Clinic proceedings.

[13]  D. Kwiatkowski,et al.  Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. , 2001, American journal of respiratory and critical care medicine.

[14]  F. McCormack Lymphangioleiomyomatosis: a clinical update. , 2008, Chest.